Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS
Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS
In 2012, it has announced the availability of the new ventilator (BiPAP- A40), which could
 offer potential advantages over fixed level pressure support, in particular, in patients with
 obesity hypoventilation syndrome (OHS). One of the key benefits of the BiPAP A40 is an
 innovative ventilation mode called AVAPS-AE, which automatically maintains airway patency
 while delivering the correct level of ventilation each user requires, whatever their body
 position or sleep stage. AVAPS-AE mode is also aimed to help the clinicians during the
 initial titration of therapy, while providing long term comfort and assuring therapy
 compliance. However, studies on the physiologic and clinical effects have not yet been
 performed. The aim of our singled-blind randomised multicentre controlled trial is to
 prospectively investigate the effects of BiPAP with the spontaneous/timed (S/T) or the
 AVAPS-AE ventilation mode over 8 weeks on sleep quality, ventilation pattern, gas exchange,
 symptoms, body composition, level of physical activity and health-related quality of life in
 OHS patients.
Efficacy on sleep quality, symptoms, physical activity and quality of life
Inclusion Criteria:

 -  Man or woman, stable patient with obesity hypoventilation syndrome, naives of non
 invasive ventilation.

 -  PaCO2 ≥ 45 mmHg.

 -  PaO2 < 70 mmHg

 -  BMI ≥ 30Kg. m2

 Exclusion Criteria:

 -  Chronic obstructive pulmonary disease

 -  Neuromuscular disease

 -  Scoliosis

 -  Cardiac insufficiency

 -  Significant psychiatric disease

 -  Sleep apnea syndrome with central apnea index > 10%

 -  Treatment with benzodiazepines at the inclusion